BRPI0416217A - composto derivado de hidroxipiperidina, métodos para a sìntese de um composto derivado de hidroxipiperidina para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase numa célula de mamìfero e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir -glicosidade, e para tratar doença de gaucher e derivado hidroxipiperidina com ligante flexìvel curto - Google Patents

composto derivado de hidroxipiperidina, métodos para a sìntese de um composto derivado de hidroxipiperidina para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase numa célula de mamìfero e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir -glicosidade, e para tratar doença de gaucher e derivado hidroxipiperidina com ligante flexìvel curto

Info

Publication number
BRPI0416217A
BRPI0416217A BRPI0416217-0A BRPI0416217A BRPI0416217A BR PI0416217 A BRPI0416217 A BR PI0416217A BR PI0416217 A BRPI0416217 A BR PI0416217A BR PI0416217 A BRPI0416217 A BR PI0416217A
Authority
BR
Brazil
Prior art keywords
hydroxypiperidine
methods
inhibit
derivative
glucocerebrosidase
Prior art date
Application number
BRPI0416217-0A
Other languages
English (en)
Inventor
Jian-Qiang Fan
Xiaoxiang Zhu
Kamlesh Sheth
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of BRPI0416217A publication Critical patent/BRPI0416217A/pt
Publication of BRPI0416217A8 publication Critical patent/BRPI0416217A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO DERIVADO DE HIDROXIPIPERIDINA, MéTODOS PARA A SìNTESE DE UM COMPOSTO DERIVADO DE HIDROXIPIPERIDINA PARA INIBIR GLICOCEREBROSIDASE, PARA AUMENTAR A ATIVIDADE DE GLICOCEREBROSIDASE NUMA CéLULA DE MAMìFERO E PARA ESTABILIZAR GLICOCEREBROSIDADE, COMPOSIçãO FARMACêUTICA, MéTODOS PARA INIBIR <225>GLICOSIDASE, E PARA TRATAR DOENçA DE GAUCHER E DERIVADO DE HIDROXIPIPERIDINA COM LIGANTE FLEXìVEL CURTO". A presente invenção refere-se a derivados de hidroxipiperidina (HP)novos com (i) uma carga positiva na posição correspondente à posição anomérica de um anel de piranose; (ii) um ligante flexível curto procedente da posição correspondente do oxigênio no anel numa piranose; e (iii) uma porção lipofílica conectada ao ligante e seus sais farmaceuticamente aceitáveis. O ligante pode estar ausente se a porção lipofílica corresponder a uma cadeia hidrocarbónica com uma extensão linear de 6 ou mais carbonos. A presente invenção provê ainda um método para tratar indivíduos com doença de Gaucher administrando-se o derivado de HP na forma de 'chaperonas' (proteínas ligantes) para a glicocerebrosidade mutante associada com a doença.
BRPI0416217A 2003-11-12 2004-11-12 composto derivado de hidroxipiperidina, métodos para a síntese de um composto derivado de hidroxipiperidina para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase numa célula de mamífero e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir beta-glicosidade, e para tratar doença de gaucher e derivado hidroxipiperidina com ligante flexível curto BRPI0416217A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51949603P 2003-11-12 2003-11-12
PCT/US2004/037704 WO2005046612A2 (en) 2003-11-12 2004-11-12 Hydroxy piperidine derivatives to treat gaucher disease

Publications (2)

Publication Number Publication Date
BRPI0416217A true BRPI0416217A (pt) 2007-01-02
BRPI0416217A8 BRPI0416217A8 (pt) 2018-05-08

Family

ID=34590422

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0416216-1A BRPI0416216A (pt) 2003-11-12 2004-11-12 composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
BRPI0416217A BRPI0416217A8 (pt) 2003-11-12 2004-11-12 composto derivado de hidroxipiperidina, métodos para a síntese de um composto derivado de hidroxipiperidina para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase numa célula de mamífero e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir beta-glicosidade, e para tratar doença de gaucher e derivado hidroxipiperidina com ligante flexível curto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0416216-1A BRPI0416216A (pt) 2003-11-12 2004-11-12 composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina

Country Status (10)

Country Link
US (3) US7741340B2 (pt)
EP (2) EP1682504B1 (pt)
JP (2) JP4767172B2 (pt)
CN (2) CN1901907A (pt)
AU (2) AU2004289327A1 (pt)
BR (2) BRPI0416216A (pt)
CA (2) CA2545435C (pt)
ES (1) ES2402182T3 (pt)
IL (2) IL175444A (pt)
WO (2) WO2005046611A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842470B2 (en) * 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2007150064A2 (en) 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
GB0622702D0 (en) * 2006-11-15 2006-12-27 Univ Dundee Selective glycosidase inhibitors
CA2683713A1 (en) * 2007-04-13 2008-10-23 Amicus Therapeutics, Inc. Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008144773A1 (en) 2007-05-22 2008-11-27 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives
WO2010118283A1 (en) * 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
MX354506B (es) 2010-12-08 2018-01-16 Us Health Pirazolopirimidinas sustituidas como activadores de glucocerebrosidasa.
US9017979B2 (en) 2011-04-11 2015-04-28 Roche Molecular Systems, Inc. DNA polymerases with improved activity
SI2707101T1 (sl) 2011-05-12 2019-06-28 Proteostasis Therapeutics, Inc. Regulatorji proteostaze
WO2013079580A1 (en) 2011-11-29 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
AU2013202368B2 (en) 2012-01-25 2016-06-16 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
AU2013240486B2 (en) * 2012-03-27 2017-10-26 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
US20150118221A1 (en) * 2012-05-08 2015-04-30 The John Hopkins University Compositions and methods for treating cardiac hypertrophy
WO2015095963A1 (en) * 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
FI3215511T3 (fi) 2014-11-06 2024-05-16 Bial R&D Invest S A Substituoituja pyratsolo(1,5-a)pyrimidiinejä ja niiden käyttö lääketieteellisten häiriöiden hoitamisessa
EP3215509B1 (en) 2014-11-06 2020-02-26 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
MX2018012208A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
EP3440080A4 (en) 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3264092A1 (en) * 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
EP3501495A1 (en) 2017-12-21 2019-06-26 InnoMedica Holding AG Liposomes comprising sphingomyelin
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente
EP3814336A1 (en) 2018-06-27 2021-05-05 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105833A (en) * 1962-04-03 1963-10-01 Grace W R & Co 4, 5-dihydroxy-piperidazines and their production
DE2848117A1 (de) * 1978-11-06 1980-05-14 Bayer Ag Derivate des 2-hydroxymethyl-3,4,5- trihydroxy-piperidins, ihre herstellung und verwendung zur beeinflussung des kohlenhydrat- und fettstoffwechsels
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US6291657B1 (en) * 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
JP3561546B2 (ja) * 1995-01-06 2004-09-02 四国化成工業株式会社 新規５，６，７，８−テトラヒドロ−イミダゾ〔１，２−ａ〕ピリジン化合物
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
WO1997031901A1 (en) * 1996-02-29 1997-09-04 Mikael Bols Hydroxyhexahydropyridazines
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
CA2305768A1 (en) * 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2001007078A1 (en) * 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2003284886A1 (en) 2002-10-21 2004-05-13 William E. Balch CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE

Also Published As

Publication number Publication date
BRPI0416216A (pt) 2006-12-26
AU2004289328B2 (en) 2011-05-19
US20100189708A1 (en) 2010-07-29
CA2545435A1 (en) 2005-05-26
CN1906162B (zh) 2012-05-23
EP1682504A2 (en) 2006-07-26
WO2005046611A2 (en) 2005-05-26
CA2545435C (en) 2014-08-19
IL175472A0 (en) 2006-09-05
BRPI0416217A8 (pt) 2018-05-08
WO2005046612A2 (en) 2005-05-26
EP1682134A4 (en) 2008-10-15
CN1906162A (zh) 2007-01-31
CA2545433A1 (en) 2005-05-26
WO2005046612A3 (en) 2005-07-14
US20050130972A1 (en) 2005-06-16
IL175444A (en) 2013-05-30
US7741340B2 (en) 2010-06-22
EP1682134A2 (en) 2006-07-26
EP1682504A4 (en) 2008-10-22
AU2004289328A1 (en) 2005-05-26
JP2007510753A (ja) 2007-04-26
IL175444A0 (en) 2006-09-05
ES2402182T3 (es) 2013-04-29
WO2005046611A3 (en) 2005-09-09
EP1682504B1 (en) 2012-12-26
AU2004289327A1 (en) 2005-05-26
US20050137223A1 (en) 2005-06-23
CN1901907A (zh) 2007-01-24
JP2007512253A (ja) 2007-05-17
JP4767172B2 (ja) 2011-09-07

Similar Documents

Publication Publication Date Title
BRPI0416217A (pt) composto derivado de hidroxipiperidina, métodos para a sìntese de um composto derivado de hidroxipiperidina para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase numa célula de mamìfero e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir -glicosidade, e para tratar doença de gaucher e derivado hidroxipiperidina com ligante flexìvel curto
RU2196769C2 (ru) Производные аминобензойной кислоты, фармацевтическая композиция
US20070203079A1 (en) Methods of using small molecule compounds for neuroprotection
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
ECSP055595A (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
ES2347581T3 (es) Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
CY1110361T1 (el) Φαρμακευτικες συνθεσεις ως αναστολεις διπεπτιδυλικης πεπτιδασης iv (dpp-iv)
Ellestad Structural and conformational features relevant to the anti‐tumor activity of calicheamicin γ
RU2005106259A (ru) Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
BRPI0508098A (pt) compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
NZ245797A (en) Substantially pure 2-methyl-4-carboxy-3,4,5,6-tetrahydropyrimidine and/or the 5-hydroxy derivative; analogues, pharmaceutical compositions, and isolation thereof from streptomyces culture
BRPI0514553A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
BRPI0511327A (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
GB1595123A (en) Heterocyclic culphones
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
DK1294402T3 (da) Forbindelser med en sulfonamidgruppe og farmaceutiske præparater indeholdende disse forbindelser
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CA2446622A1 (en) Isostearic acid salts as permeation enhancers
BR9804753A (pt) Compostos de ácido picolìnico 5-substituìdo e processos para a sua produção.
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
US7968733B2 (en) Pyrrolidine analogue for preventing neurogenic pain and method for production thereof
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]